南方医科大学学报

南方医科大学学报 ›› 2006, Vol. 26 ›› Issue (05): 689-691.

• • 上一篇    下一篇

贝伐单抗联合伊立替康治疗转移性结直肠癌的近期疗效观察

郑航； 陈锦章； 廖旺军； 罗荣城；   

  1. 南方医科大学南方医院肿瘤中心； 南方医科大学南方医院肿瘤中心 广东广州510515； 广东广州510515；
  • 出版日期:2006-05-20 发布日期:2006-05-20

Efficacy of Avastin in combination with irinotecan for metastatic colorectal cancer

ZHENG Hang,CHEN Jin-zhang,LIAO Wang-jun,LUO Rong-cheng Center of Oncology,Nanfang Hospital,Southern Medical University,Guangzhou 510515,China   

  1. 南方医科大学南方医院肿瘤中心； 南方医科大学南方医院肿瘤中心 广东广州510515； 广东广州510515；
  • Online:2006-05-20 Published:2006-05-20

PDF

2055

摘要： 目的探讨贝伐单抗联合伊立替康治疗转移性结直肠癌的疗效。方法90例患者随机分为3组,30例给予贝伐单抗联合伊立替康治疗(A组),30例使用FOLFIRI方案治疗(B组),30例使用FOLFOX7方案治疗(C组),均给予6个周期治疗。观察患者治疗前后血清肿瘤标志物的动态变化和近期疗效。结果A组有效率为43.3%,疾病控制率80%;B组有效率为27.7%,疾病控制率53.3%;C组有效率为30.0%,疾病控制率50.0%。3组肿瘤标志物的浓度治疗前后均有明显变化,以A组最为显著(P<0.05)。结论贝伐联合伊立替康治疗转移性结直肠癌具有更高的疾病控制率。 

Abstract: Objective To evaluate the efficacy of Avastin in combination with irinotecan for metastatic colorectal cancer.Methods Ninety patients were randomly divided into 3 equal groups to receive Avastin plus irinotecan(group A),FOLFIRI(group B)and FOLFOX7(group C)for two cycles,respectively.The response rate and changes in tumor maker levels were observed.Results The tumor response rate was 43.3% in group A,27.7% in group B and 30.0% in group C.The disease control rate(complete response+partial response+stable disease)was 80% in group A,53.3% in group B and 50.0% in group C.Obvious changes in tumor marker levels were observed in the 3 groups after treatment,which were most conspicuous in group A(P<0.05).Conclusion The addition of Avastin to irinotecan chemotherapy results in significant improvement of clinical efficacy in patients with metastatic colorectal cancer. 

中图分类号: